

Annexure

References-

- [1] N. Bachtel and K. Israni-Winger, “Plant-based medicine and pharmacology,” *Yale Journal of Biology and Medicine*, vol. 93, no. 2, pp. 227–228, 2020.
- [2] L. A. Petrillo, C. S. Ritchie, F. Veterans, A. Medical, S. Francisco, and S. Francisco, “multimorbidity in research and practice : a thematic review,” vol. 24, no. 5, pp. 262–267, 2017, doi: 10.1080/09699260.2016.1192320.The.
- [3] D. A. Dias, S. Urban, and U. Roessner, “A Historical overview of natural products in drug discovery,” *Metabolites*, vol. 2, no. 2, pp. 303–336, 2012, doi: 10.3390/metabo2020303.
- [4] S. Kim, S. W. Lim, and J. Choi, “Drug discovery inspired by bioactive small molecules from nature,” *Animal Cells and Systems*, vol. 26, no. 6, pp. 254–265, 2022, doi: 10.1080/19768354.2022.2157480.
- [5] A. L. Svalastog, D. Donev, N. J. Kristoffersen, and S. Gajović, “Concepts and definitions of health and health-related values in the knowledge landscapes of the digital society,” *Croatian Medical Journal*, vol. 58, no. 6, pp. 431–435, 2017, doi: 10.3325/cmj.2017.58.431.
- [6] R. M. WATROUS, “Health hazards of the pharmaceutical industry.,” *British journal of industrial medicine*, vol. 4, no. 2, pp. 111–125, 1947, doi: 10.4172/2167-7689.1000145.
- [7] R. J. L. Heron and F. C. Pickering, “Health effects of exposure to active pharmaceutical ingredients (APIs),” *Occupational Medicine*, vol. 53, no. 6, pp. 357–362, 2003, doi: 10.1093/occmed/kqg115.
- [8] A. S. van Wyk and G. Prinsloo, “Health, safety and quality concerns of plant-based traditional medicines and herbal remedies,” *South African Journal of Botany*, vol. 133, pp. 54–62, 2020, doi: 10.1016/j.sajb.2020.06.031.
- [9] B. S. Alotaibi, M. Ijaz, M. Buabeid, Z. J. Kharaba, H. S. Yaseen, and G. Murtaza, “Therapeutic effects and safe uses of plant-derived polyphenolic compounds in cardiovascular diseases: A review,” *Drug Design, Development and Therapy*, vol. 15, pp. 4713–4732, 2021, doi: 10.2147/DDDT.S327238.
- [10] L. de A. A. Freitas and G. Radis-Baptista, “Pharmaceutical pollution and disposal of expired, unused, and unwanted medicines in the Brazilian context,” *Journal of Xenobiotics*, vol. 11, no. 2, pp. 61–76, 2021, doi: 10.3390/jox11020005.

- [11] D. G. J. Larsson, "Assessing risks and impacts of pharmaceuticals in the environment on wildlife and ecosystems". Pollution from drug manufacturing: review and perspectives," *Phil. Trans. R. Soc. B*, vol. 369, 2014.
- [12] M. Krzywonos and K. Piwowar-Sulej, "Plant-Based Innovations for the Transition to Sustainability: A Bibliometric and in-Depth Content Analysis," *Foods*, vol. 11, no. 19, 2022, doi: 10.3390/foods11193137.
- [13] C. G. Daughton, "Eco-directed sustainable prescribing: Feasibility for reducing water contamination by drugs," *Science of the Total Environment*, vol. 493, pp. 392–404, 2014, doi: 10.1016/j.scitotenv.2014.06.013.
- [14] Jürg Oliver Straub, *Protein and Peptide Therapeutics: An Example of "Benign by Nature" Active Pharmaceutical Ingredients*. 2010.
- [15] T. Arora *et al.*, "Substitute of animals in drug research: An approach towards fulfilment of 4R's," *Indian Journal of Pharmaceutical Sciences*, vol. 73, no. 1, pp. 1–6, 2011, doi: 10.4103/0250-474x.89750.
- [16] T. T. Medicine and N. Products, "The Traditional Medicine and Modern Medicine from Natural Products," 2016, doi: 10.3390/molecules21050559.
- [17] T. B. Tufa, F. Regassa, K. Amenu, J. A. Stegeman, and H. Hogeveen, "Livestock producers' knowledge, attitude, and behavior (KAB) regarding antimicrobial use in Ethiopia," *Frontiers in Veterinary Science*, vol. 10, pp. 1–20, 2023, doi: 10.3389/fvets.2023.1167847.
- [18] W. Wang *et al.*, "Antibiotic resistance : a rundown of a global crisis," *Infection and Drug Resistance*, vol. 11, pp. 1645–1658, 2018.
- [19] H. M. Al Alsheikh *et al.*, "Plant-based phytochemicals as possible alternative to antibiotics in combating bacterial drug resistance," *Antibiotics*, vol. 9, no. 8, pp. 1–23, 2020, doi: 10.3390/antibiotics9080480.
- [20] N. Vaou, E. Stavropoulou, C. Voidarou, C. Tsigalou, and E. Bezirtzoglou, "Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives," *Microorganisms*, vol. 9, no. 10, pp. 1–28, 2021, doi: 10.3390/microorganisms9102041.

- [21] P. J. Tusso, M. H. Ismail, B. P. Ha, and C. Bartolotto, "Nutritional update for physicians: plant-based diets.," *The Permanente journal*, vol. 17, no. 2, pp. 61–66, 2013, doi: 10.7812/TPP/12-085.
- [22] V. Chander, J. S. Aswal, R. Dobhal, and D. P. Uniyal, "A review on Pharmacological potential of Berberine ; an active component of Himalayan *Berberis aristata*," vol. 6, no. 1, pp. 53–58, 2017.
- [23] P. Mazumder, S. Das, S. Das, and M. Das, "PHYTO-PHARMACOLOGY of *Berberis aristata* DC: A REVIEW," *Journal of Drug Delivery and Therapeutics*, vol. 1, p. null, 2011, doi: 10.22270/JDDT.V1I2.34.
- [24] Z.-B. Yi, Y. Yu, Y.-Z. Liang, and B. Zeng, "Evaluation of the antimicrobial mode of berberine by LC/ESI-MS combined with principal component analysis.," *Journal of pharmaceutical and biomedical analysis*, vol. 44, no. 1, pp. 301–304, May 2007, doi: 10.1016/j.jpba.2007.02.018.
- [25] L. Herrmann, F. Hahn, C. Wangen, M. Marschall, and S. B. Tsogoeva, "Anti-SARS-CoV-2 Inhibitory Profile of New Quinoline Compounds in Cell Culture-Based Infection Models," *Chemistry - A European Journal*, vol. 28, no. 4, 2022, doi: 10.1002/chem.202103861.
- [26] S. Habtemariam, "Berberine and inflammatory bowel disease: A concise review," *Pharmacological Research*, vol. 113, pp. 592–599, 2016, doi: <https://doi.org/10.1016/j.phrs.2016.09.041>.
- [27] K. Zou *et al.*, "Advances in the study of berberine and its derivatives: A focus on anti-inflammatory and anti-tumor effects in the digestive system," *Acta Pharmacologica Sinica*, vol. 38, no. 2, pp. 157–167, 2017, doi: 10.1038/aps.2016.125.
- [28] L. R. Bhatt, B. Wagle, M. Adhikari, S. Bhusal, A. Giri, and S. Bhattarai, "Antioxidant activity, total phenolic and flavonoid content of *Berberis aristata* DC. and *Berberis thomsoniana* C.K. Schneid. from Sagarmatha National Park, Nepal," *Pharmacognosy Journal*, vol. 10, no. 6, pp. S167–S171, 2018, doi: 10.5530/pj.2018.6s.29.
- [29] B. Semwal, J. Gupta, S. Singh, Y. Kumar, and M. Giri, "Antihyperglycemic activity of root of *Berberis aristata* D.C. in alloxan-induced diabetic rats," *International Journal of Green Pharmacy*, vol. 3, no. 3, pp. 259–262, 2009, doi: 10.4103/0973-8258.56288.

- [30] Z. Moazezi and D. Qujeq, "Berberis fruit extract and biochemical parameters in patients with type II diabetes," *Jundishapur Journal of Natural Pharmaceutical Products*, vol. 9, no. 2, 2014, doi: 10.17795/jjnpp-13490.
- [31] I. Khan, A. Qayum, and Z. Qureshi, "Study of the hypotensive action of berbamine, an alkaloid isolated from berberis lycium.," *Life sciences*, vol. 8, no. 17, pp. 993–1001, Sep. 1969, doi: 10.1016/0024-3205(69)90432-9.
- [32] F. Jahan, S. S. Alvi, and M. H. Islam, "*Berberis aristata* and its secondary metabolites: Insights into nutraceutical and therapeutical applications," *Pharmacological Research - Modern Chinese Medicine*, vol. 5, no. October, p. 100184, 2022, doi: 10.1016/j.prmcm.2022.100184.
- [33] C. Seger, S. Sturm, and H. Stuppner, "Mass spectrometry and NMR spectroscopy: Modern high-end detectors for high resolution separation techniques-state of the art in natural product HPLC-MS, HPLC-NMR, and CE-MS hyphenations," *Natural Product Reports*, vol. 30, no. 7, pp. 970–987, 2013, doi: 10.1039/c3np70015a.
- [34] J. L. Wolfender, J. M. Nuzillard, J. J. J. Van Der Hooft, J. H. Renault, and S. Bertrand, "Accelerating Metabolite Identification in Natural Product Research: Toward an Ideal Combination of Liquid Chromatography-High-Resolution Tandem Mass Spectrometry and NMR Profiling, in Silico Databases, and Chemometrics," *Analytical Chemistry*, vol. 91, no. 1, pp. 704–742, 2019, doi: 10.1021/acs.analchem.8b05112.
- [35] S. Moco *et al.*, "A liquid chromatography-mass spectrometry-based metabolome database for tomato," *Plant Physiology*, vol. 141, no. 4, pp. 1205–1218, 2006, doi: 10.1104/pp.106.078428.
- [36] S. Gill, A. Christopher, V. Gupta, and P. Bansal, "Emerging role of bioinformatics tools and software in evolution of clinical research," *Perspectives in Clinical Research*, vol. 7, no. 3, p. 115, 2016, doi: 10.4103/2229-3485.184782.
- [37] B. V. Bonifácio, P. B. da Silva, M. A. dos S. Ramos, K. M. S. Negri, T. M. Bauab, and MarlusChorilli, "Nanotechnology-based drug delivery systems and herbal medicines : a review," *International Journal of Nanomedicine*, vol. 9, pp. 1–15, 2014.

- [38] M. K. Dewi, A. Y. Chaerunisaa, M. Muhaimin, and I. M. Joni, “Improved Activity of Herbal Medicines through Nanotechnology.pdf,” *Nanomaterials*, vol. 12, pp. 1–19, 2022.
- [39] X. A. Qu, J. M. Freudenberg, P. Sanseau, and D. K. Rajpal, “Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study,” *Drug Discovery Today*, vol. 19, no. 9, pp. 1364–1371, 2014, doi: <https://doi.org/10.1016/j.drudis.2014.03.015>.
- [40] J. Guo, Z. Huang, J. Sun, X. Cui, and Y. Liu, “Research Progress and Future Development Trends in Medicinal Plant Transcriptomics,” *Frontiers in Plant Science*, vol. 12, no. July, pp. 1–10, 2021, doi: 10.3389/fpls.2021.691838.
- [41] P. Tyagi, D. Singh, S. Mathur, A. Singh, and R. Ranjan, “Upcoming progress of transcriptomics studies on plants: An overview,” *Frontiers in Plant Science*, vol. 13, no. December, pp. 1–15, 2022, doi: 10.3389/fpls.2022.1030890.
- [42] N. De Tommasi, C. Sinisgalli, L. Milella, and J. Rajkovic, “Berberis Plants — Drifting from Farm to Food,” *Foods*, vol. 8, p. 522, 2019.
- [43] Y. K. Li, J. Harber, C. Peng, Z. Q. Du, Y. W. Xing, and C. C. Yu, “Taxonomic synopsis of Berberis (Berberidaceae) from the northern Hengduan mountains region in China, with descriptions of seven new species,” *Plant Diversity*, vol. 44, no. 5, pp. 505–517, 2022, doi: 10.1016/j.pld.2022.03.002.
- [44] S. Hasham, S. Nilima, and G. Santosh, “Introduction :,” vol. 3, no. 5, pp. 60–69, 2022.
- [45] U. Inserm, H. Saint, and V. De Paul, “Diabetologia,” pp. 503–509, 1993.
- [46] G. Sarma and M. Sarma, “Pre & Post Vedic Plants Used in Diabetes-a Data Base Study,” *Iamj.in*.
- [47] S. R. Kumar, “Herbs Used for Management of Diabetes in Siddha System of Medicine-a Review,” *Certified Journal | 843 World Journal of Pharmaceutical Research SJIF Impact Factor*, vol. 11, no. 5, pp. 843–852, 2022, doi: 10.20959/wjpr20225-23932.
- [48] A. Gordon, Z. Buch, V. Baute, and R. Coeytaux, “Use of Ayurveda in the Treatment of Type 2 Diabetes Mellitus,” *Global Advances in Health and Medicine*, vol. 8, p. 2164956119861094, Jan. 2019, doi: 10.1177/2164956119861094.

- [49] B. Elya *et al.*, “Antidiabetic activity and phytochemical screening of extracts from Indonesian plants by inhibition of alpha amylase, alpha glucosidase and dipeptidyl peptidase IV,” *Pakistan Journal of Biological Sciences*, vol. 18, no. 6, pp. 273–278, 2015, doi: 10.3923/pjbs.2015.279.284.
- [50] T. Khan, I. A. Khan, and A. Rehman, “A review on *Berberis* species reported from Gilgit-Baltistan and Central Karakoram National Park, Pakistan,” *Journal of Medicinal Plants*, vol. 2, no. 6, pp. 16–20, 2014.
- [51] S. Komal, B. Ranjan, C. Neelam, S. Birendra, and S. N. Kumar, “*Berberis aristata*: A review,” *Int J Res Ayurveda Pharm*, vol. 2, no. 2, pp. 383–388, 2011.
- [52] A. Badoni and M. K. Arya, “Insects visiting the medicinal plants from genus *Berberis L.* in the Western Himalaya,” *Oriental Insects*, vol. 56, no. 1, pp. 1–13, Jan. 2022, doi: 10.1080/00305316.2020.1860148.
- [53] A. Haji and M. Rahimi, “RSM Optimization of Wool Dyeing with *Berberis Thunbergii DC* Leaves as a New Source of Natural Dye,” *Journal of Natural Fibers*, vol. 19, no. 8, pp. 2785–2798, Aug. 2022, doi: 10.1080/15440478.2020.1821293.
- [54] L. Sheneman and A. Hintze, “Comprehensive Review of Plasticity,” vol. 8, no. 5, pp. 12–14, 2016.
- [55] N. Mokhber-Dezfuli, S. Saeidnia, A. Gohari, and M. Kurepaz-Mahmoodabadi, “Phytochemistry and pharmacology of *Berberis* species,” *Pharmacognosy Reviews*, vol. 8, no. 15, pp. 8–15, 2014, doi: 10.4103/0973-7847.125517.
- [56] M. Rizwan, A. Khan, H. Nasir, A. Javed, and S. Z. Shah, “Phytochemical and biological screening of *Berberis aristata*,” *Advancements in Life Sciences*, vol. 5, pp. 1–7, 2017.
- [57] H. Tomosaka, Y.-W. Chin, A. A. Salim, W. J. Keller, H. Chai, and A. D. Kinghorn, “Antioxidant and cytoprotective compounds from *Berberis vulgaris* (barberry),” *Phytotherapy Research*, vol. 22, no. 7, pp. 979–981, 2008, doi: <https://doi.org/10.1002/ptr.2443>.
- [58] M. Masood and K. P. Tiwari, “2,5-Bis-(2'-methoxy-5'-methylphenyl)-furan, a rare type of compound from *Berberis umbellata*,” *Phytochemistry*, vol. 20, no. 2, pp. 295–296, 1981, doi: [https://doi.org/10.1016/0031-9422\(81\)85110-2](https://doi.org/10.1016/0031-9422(81)85110-2).

- [59] I. N. B. Berberidaceae, “Review article : A REVIEW ON BIOLOGICAL AND CHEMICAL DIVERSITY,” *EXCLI Journal*, pp. 247–267, 2015.
- [60] N. Zhao, S. Isguven, R. Evans, T. P. Schaer, and N. J. Hickok, “Berberine disrupts staphylococcal proton motive force to cause potent anti-staphylococcal effects in vitro,” *Biofilm*, vol. 5, no. March, p. 100117, 2023, doi: 10.1016/j.bioflm.2023.100117.
- [61] S. Manandhar, S. Luitel, and R. K. Dahal, “In Vitro Antimicrobial Activity of Some Medicinal Plants against Human Pathogenic Bacteria,” *Journal of Tropical Medicine*, vol. 2019, 2019, doi: 10.1155/2019/1895340.
- [62] P. Thakur, R. Chawla, A. Narula, R. Goel, R. Arora, and R. K. Sharma, “No Title,” *Journal of Complementary and Integrative Medicine*, vol. 13, no. 3, pp. 229–237, 2016, doi: 10.1515/jcim-2015-0066.
- [63] A. Warowicka, R. Nawrot, and A. Goździcka-Józefiak, “Antiviral activity of berberine,” *Archives of Virology*, vol. 165, no. 9, pp. 1935–1945, 2020, doi: 10.1007/s00705-020-04706-3.
- [64] S. H. Kim, D. S. Shin, M. N. Oh, S. C. Chung, J. S. Lee, and K. B. Oh, “Inhibition of the bacterial surface protein anchoring transpeptidase sortase by isoquinoline alkaloids,” *Bioscience, Biotechnology and Biochemistry*, vol. 68, no. 2, pp. 421–424, 2004, doi: 10.1271/bbb.68.421.
- [65] K. Chester, S. Zahiruddin, A. Ahmad, W. Khan, S. Paliwal, and S. Ahmad, “Bioautography-based Identification of Antioxidant Metabolites of *Solanum nigrum L.* and Exploration Its Hepatoprotective Potential agChester, K. et al. (2017) ‘Bioautography-based Identification of Antioxidant Metabolites of *Solanum nigrum L.* and Explorati,” *Pharmacognosy Magazine*, vol. 13 (Suppl, no. 62, pp. 179–188, 2017, doi: 10.4103/pm.pm.
- [66] S. K. Gupta *et al.*, “The anti-inflammatory effects of *Curcuma longa* and *Berberis aristata* in endotoxin-induced uveitis in rabbits,” *Investigative Ophthalmology and Visual Science*, vol. 49, no. 9, pp. 4036–4040, 2008, doi: 10.1167/iovs.07-1186.
- [67] Y. Wang, W. Gong, S. Lv, H. Qu, and Y. He, “Berberine improves insulin resistance in adipocyte models by regulating the methylation of hypoxia-inducible factor-3a,” *Bioscience Reports*, vol. 39, no. 10, pp. 1–13, 2019, doi: 10.1042/BSR20192059.

- [68] S. H. Kathem, W. K. Abdulsahib, and M. H. Zalzal, "Berbamine and thymoquinone exert protective effects against immune-mediated liver injury via NF- κ B dependent pathway," *Frontiers in Veterinary Science*, vol. 9, 2022, doi: 10.3389/fvets.2022.960981.
- [69] X. J. Jia, X. Li, F. Wang, H. Q. Liu, D. J. Zhang, and Y. Chen, "Berbamine exerts anti-inflammatory effects via inhibition of NF- κ B and MAPK signaling pathways," *Cellular Physiology and Biochemistry*, vol. 41, no. 6, pp. 2307–2318, 2017, doi: 10.1159/000475650.
- [70] C. R. Zhang, R. E. Schutzki, and M. G. Nair, "Antioxidant and anti-inflammatory compounds in the popular landscape plant *Berberis thunbergii* var. *atropurpurea*," *Natural Product Communications*, vol. 8, no. 2, pp. 165–168, 2013, doi: 10.1177/1934578x1300800207.
- [71] V. Baradaran Rahimi and V. R. Askari, "Role of Herbal Medicines for the Treatment of Arthritis," in *Role of Herbal Medicines : Management of Lifestyle Diseases*, A. K. Dhara and S. C. Mandal, Eds., Singapore: Springer Nature Singapore, 2023, pp. 271–292. doi: 10.1007/978-981-99-7703-1_14.
- [72] W. Zhuang *et al.*, "Berberine exerts antioxidant effects via protection of spiral ganglion cells against cytomegalovirus-induced apoptosis," *Free Radical Biology and Medicine*, vol. 121, pp. 127–135, 2018, doi: <https://doi.org/10.1016/j.freeradbiomed.2018.04.575>.
- [73] P. Sharma *et al.*, "Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants.," *American journal of translational research*, vol. 15, no. 11, pp. 6321–6341, 2023.
- [74] E. Tian, G. Sharma, and C. Dai, "Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications.," *Antioxidants (Basel, Switzerland)*, vol. 12, no. 10, Oct. 2023, doi: 10.3390/antiox12101883.
- [75] B. Yan *et al.*, "Palmatine inhibits TRIF-dependent NF- κ B pathway against inflammation induced by LPS in goat endometrial epithelial cells," *International Immunopharmacology*, vol. 45, pp. 194–200, 2017, doi: <https://doi.org/10.1016/j.intimp.2017.02.004>.
- [76] P. Hasanein, M. Ghafari-Vahed, and I. Khodadadi, "Effects of isoquinoline alkaloid berberine on lipid peroxidation, antioxidant defense system, and liver damage induced by lead acetate in rats.," *Redox report : communications in free radical research*, vol. 22, no. 1, pp. 42–50, Jan. 2017, doi: 10.1080/13510002.2016.1140406.

- [77] P. Hasanein, M. Ghafari-Vahed, and I. Khodadadi, "Effects of isoquinoline alkaloid berberine on lipid peroxidation, antioxidant defense system, and liver damage induced by lead acetate in rats," *Redox Report*, vol. 22, no. 1, pp. 42–50, 2017, doi: 10.1080/13510002.2016.1140406.
- [78] R. Pradeepa and V. Mohan, "Epidemiology of type 2 diabetes in India," *Indian Journal of Ophthalmology*, vol. 69, no. 11, 2021.
- [79] F. Di Pierro, P. Putignano, N. Villanova, L. Montesi, S. Moscatiello, and G. Marchesini, "Preliminary study about the possible glycemetic clinical advantage in using a fixed combination of *Berberis aristata* and *Silybum marianum* standardized extracts versus only *Berberis aristata* in patients with type 2 diabetes.," *Clinical pharmacology : advances and applications*, vol. 5, pp. 167–174, 2013, doi: 10.2147/CPAA.S54308.
- [80] T. Belwal *et al.*, "Phytopharmacology and Clinical Updates of Berberis Species Against Diabetes and Other Metabolic Diseases.," *Frontiers in pharmacology*, vol. 11, p. 41, 2020, doi: 10.3389/fphar.2020.00041.
- [81] S. Shrivastava, A. Sharma, N. Saxena, R. Bhamra, and S. Kumar, "Addressing the preventive and therapeutic perspective of berberine against diabetes.," *Heliyon*, vol. 9, no. 11, p. e21233, Nov. 2023, doi: 10.1016/j.heliyon.2023.e21233.
- [82] J. Yin, H. Xing, and J. Ye, "Efficacy of berberine in patients with type 2 diabetes mellitus.," *Metabolism: clinical and experimental*, vol. 57, no. 5, pp. 712–717, May 2008, doi: 10.1016/j.metabol.2008.01.013.
- [83] G. Derosa, G. Gaudio, A. D. ' Angelo, and P. Maffioli, "Efficacy of *Berberis aristata* Compared to Metformin in Improving Glycemic Control and Insulin Resistance in Patients with Type 2 Diabetes Mellitus Compared to Metformin in Improving Glycemic Control and Insulin Resistance in Patients with Type 2 Diabetes Mellitus," *Journal of Food and Nutrition Research*, vol. 8, no. 4, pp. 212–215, 2020, doi: 10.12691/jfnr-8-4-8.
- [84] C. Sankaranarayanan, R. Nishanthi, and P. Pugalendi, "Ameliorating effect of berbamine on hepatic key enzymes of carbohydrate metabolism in high-fat diet and streptozotocin induced type 2 diabetic rats," *Biomedicine & Pharmacotherapy*, vol. 103, pp. 539–545, 2018, doi: <https://doi.org/10.1016/j.biopha.2018.04.066>.

- [85] J. Rolle *et al.*, “Jatrorrhizine: A review of its pharmacological effects,” *Journal of Pharmacy and Pharmacology*, vol. 73, no. 6, pp. 709–719, 2021, doi: 10.1093/jpp/rgaa065.
- [86] P. S. Houts, R. E. Lenhard, and C. Varricchio, “ACS cancer facts and figures,” *Cancer Practice*, vol. 8, no. 3, pp. 105–108, 2000, doi: 10.1046/j.1523-5394.2000.83001.x.
- [87] C. Yuan *et al.*, “Chinese Medicine Phenomics (Chinmedphenomics): Personalized, Precise and Promising,” *Phenomics*, vol. 2, no. 6, pp. 383–388, 2022, doi: 10.1007/s43657-022-00074-x.
- [88] Nobuji Nakatani, “Phenolic antioxidants from herbs and spices,” *BioFactors*, vol. 13, pp. 141–146, 2000.
- [89] P. Balachandran and R. Govindarajan, “Cancer - An ayurvedic perspective,” *Pharmacological Research*, vol. 51, no. 1, pp. 19–30, 2005, doi: 10.1016/j.phrs.2004.04.010.
- [90] W. Ying, “Phenomic Studies on Diseases: Potential and Challenges,” *Phenomics*, vol. 3, no. 3, pp. 285–299, 2023, doi: 10.1007/s43657-022-00089-4.
- [91] J. K. S. Ko, W. C. Leung, W. K. Ho, and P. Chiu, “Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene,” *European Journal of Pharmacology*, vol. 559, no. 1, pp. 1–13, 2007, doi: 10.1016/j.ejphar.2006.12.004.
- [92] S. Kainsa, P. Kumar, and P. Rani, “Medicinal Plants of Asian Origin Having Anticancer Potential: Short Review,” *Asian Journal of Biomedical and Pharmaceutical Sciences*, vol. 2, no. 10, pp. 1–7, 2012.
- [93] M. S. Othman, S. T. Obeidat, A. H. Al-Bagawi, M. A. Fareid, A. Fehaid, and A. E. Abdel Moneim, “Green-synthesized selenium nanoparticles using berberine as a promising anticancer agent,” *Journal of integrative medicine*, vol. 20, no. 1, pp. 65–72, Jan. 2022, doi: 10.1016/j.joim.2021.11.002.
- [94] J. Tavakoli, S. Miar, M. M. Zadehzare, and H. Akbari, “Evaluation of effectiveness of herbal medication in cancer care: A review study,” *Iranian Journal of Cancer Prevention*, vol. 5, no. 3, pp. 144–156, 2012.
- [95] B. Lamichhane, S. Adhikari, P. Shrestha, and B. Govinda Shrestha, “Study of phytochemical, antioxidant, antimicrobial and anticancer activity of *Berberis aristata*,” *Journal of Tropical Life Science*, vol. 4, no. 1, pp. 01–07, 2014, doi: 10.11594/jtls.04.01.01.

- [96] C. Borek, "Dietary antioxidants and human cancer," *Integrative Cancer Therapies*, vol. 3, no. 4, pp. 333–341, 2004, doi: 10.1177/1534735404270578.
- [97] R. Kaur, K. Kapoor, and H. Kaur, "Plants as a source of anticancer agents," vol. 1, no. 1, pp. 119–124, 2011.
- [98] Z. Meng *et al.*, "Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase II," *Molecular Cancer Therapeutics*, vol. 12, no. 10, pp. 2067–2077, 2013, doi: 10.1158/1535-7163.MCT-13-0314.
- [99] C. Liu, P. Xiao, and G. Liu, "Studies on plant resources, pharmacology and clinical treatment with berbamine," *Phytotherapy Research*, vol. 5, no. 5, pp. 228–230, 1991.
- [100] J. Long, J. Song, L. Zhong, Y. Liao, L. Liu, and X. Li, "Palmatine: A review of its pharmacology, toxicity and pharmacokinetics," *Biochimie*, vol. 162, pp. 176–184, 2019, doi: <https://doi.org/10.1016/j.biochi.2019.04.008>.
- [101] A. Grabarska *et al.*, "Palmatine, a Bioactive Protoberberine Alkaloid Isolated from *Berberis cretica*, Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells and Acts Synergistically and Additively with Doxorubicin," *Molecules*, vol. 26, no. 20, 2021, doi: 10.3390/molecules26206253.
- [102] C.-L. Kuo, C.-W. Chi, and T.-Y. Liu, "The anti-inflammatory potential of berberine in vitro and in vivo," *Cancer Letters*, vol. 203, no. 2, pp. 127–137, 2004, doi: <https://doi.org/10.1016/j.canlet.2003.09.002>.
- [103] W. X. Jiang, S. H. Li, and X. J. Li, "Therapeutic potential of berberine against neurodegenerative diseases," *Science China Life Sciences*, vol. 58, no. 6, pp. 564–569, 2015, doi: 10.1007/s11427-015-4829-0.
- [104] S. Mehdi, M. H. Mehmood, M. G. Ahmed, and U. A. Ashfaq, "Antidiabetic activity of *Berberis brandisiana* is possibly mediated through modulation of insulin signaling pathway, inflammatory cytokines and adipocytokines in high fat diet and streptozotocin-administered rats," *Frontiers in Pharmacology*, vol. 14, no. April, pp. 1–18, 2023, doi: 10.3389/fphar.2023.1085013.
- [105] R. Haselgrübler *et al.*, "Hypolipidemic effects of herbal extracts by reduction of adipocyte differentiation, intracellular neutral lipid content, lipolysis, fatty acid exchange and lipid

- droplet motility,” *Scientific Reports*, vol. 9, no. 1, pp. 1–18, 2019, doi: 10.1038/s41598-019-47060-4.
- [106] E. Lo Piparo, H. Scheib, N. Frei, G. Williamson, M. Grigorov, and C. J. Chou, “Flavonoids for controlling starch digestion: Structural requirements for inhibiting human α -amylase,” *Journal of Medicinal Chemistry*, vol. 51, no. 12, pp. 3555–3561, 2008, doi: 10.1021/jm800115x.
- [107] Y. Patrice Didion, T. Gijsbert Tjalsma, Z. Su, M. Malankowska, and M. Pinelo, “What is next? the greener future of solid liquid extraction of biobased compounds: Novel techniques and solvents overpower traditional ones,” *Separation and Purification Technology*, vol. 320, p. 124147, 2023, doi: <https://doi.org/10.1016/j.seppur.2023.124147>.
- [108] R. J. Chadwick, “Co Re Co Re,” *Europe*, vol. 2018, no. September, pp. 2–5, 2007.
- [109] I. Funke and M. F. Melzig, “Traditionally used plants in diabetes therapy: phytotherapeutics as inhibitors of alpha-amylase activity,” *Revista Brasileira de Farmacognosia*, vol. 16, no. 1, pp. 1–5, 2006, doi: 10.1590/s0102-695x2006000100002.
- [110] L. Groop, “Characterization of the Prediabetic State,” *American Journal of Hypertension*, vol. 10, no. 12, pp. 172S-180S, 1997, doi: 10.1016/s0895-7061(97)00149-0.
- [111] N. D. S. Report, “National Diabetes Statistics Report, 2020,” *National Diabetes Statistics Report*, p. 2, 2020.
- [112] J. Hippisley-Cox and C. Coupland, “Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care,” *BMJ*, vol. 352, p. i1450, Mar. 2016, doi: 10.1136/bmj.i1450.
- [113] D. R. Chhetri, P. Parajuli, and G. C. Subba, “Antidiabetic plants used by Sikkim and Darjeeling Himalayan tribes, India,” *Journal of Ethnopharmacology*, vol. 99, no. 2, pp. 199–202, 2005.
- [114] S. Venkatesh, G. D. Reddy, B. M. Reddy, M. Ramesh, and A. V. N. A. Rao, “Antihyperglycemic activity of *Caralluma attenuata*,” *Fitoterapia*, vol. 74, no. 3, pp. 274–279, 2003.
- [115] E. C. Jeyaseelan, S. Jenothiny, M. K. Pathmanathan, and J. P. Jeyadevan, “Antibacterial activity of sequentially extracted organic solvent extracts of fruits, flowers and leaves of

- Lawsonia inermis* L. from Jaffna,” *Asian Pacific Journal of Tropical Biomedicine*, vol. 2, no. 10, pp. 798–802, 2012, doi: 10.1016/S2221-1691(12)60232-9.
- [116] A. Nn, “A Review on the Extraction Methods Use in Medicinal Plants, Principle, Strength and Limitation,” *Medicinal & Aromatic Plants*, vol. 04, no. 03, pp. 3–8, 2015, doi: 10.4172/2167-0412.1000196.
- [117] B. Lamichhane, S. Adhikari, P. Shrestha, and B. Govinda Shrestha, “Study of phytochemical, antioxidant, antimicrobial and anticancer activity of *Berberis aristata*,” *Journal of Tropical Life Science*, vol. 4, no. 1, pp. 01–07, 2014, doi: 10.11594/jtls.04.01.01.
- [118] B. Columbia *et al.*, “Pharmacognostical and Phytochemical Evaluation,” vol. 5, no. 3, pp. 1631–1636, 2011.
- [119] K. Slinkard and V. L. Singleton, “Total Phenol Analysis: Automation and Comparison with Manual Methods,” *American Journal of Enology and Viticulture*, vol. 28, no. 1, pp. 49 LP – 55, Jan. 1977.
- [120] D. Ahmed, M. M. Khan, and R. Saeed, “Comparative analysis of phenolics, flavonoids, and antioxidant and antibacterial potential of methanolic, hexanic and aqueous extracts from *Adiantum caudatum* leaves,” *Antioxidants*, vol. 4, no. 2, pp. 394–409, 2015, doi: 10.3390/antiox4020394.
- [121] T. Shimamura *et al.*, “Applicability of the DPPH assay for evaluating the antioxidant capacity of food additives - inter-laboratory evaluation study,” *Analytical Sciences*, vol. 30, no. 7, pp. 717–721, 2014, doi: 10.2116/analsci.30.717.
- [122] X. J. Li and S. Y. Cui, “DPPH radical scavenging mechanism of ascorbic acid,” *Food Science*, vol. 1, pp. 86–90, 2011.
- [123] C. Aydoğan, “Recent advances and applications in LC-HRMS for food and plant natural products: a critical review,” *Analytical and Bioanalytical Chemistry*, vol. 412, no. 9, pp. 1973–1991, 2020, doi: 10.1007/s00216-019-02328-6.
- [124] P. Lucci, J. Saurina, and O. Núñez, “Trends in LC-MS and LC-HRMS analysis and characterization of polyphenols in food,” *TrAC - Trends in Analytical Chemistry*, vol. 88, pp. 1–24, 2017, doi: 10.1016/j.trac.2016.12.006.

- [125] E. Tamboli, A. Bhatnagar, and A. Mishra, "Alpha-amylase inhibitors from mycelium of an oyster mushroom," *Preparative Biochemistry and Biotechnology*, vol. 48, no. 8, pp. 693–699, 2018.
- [126] A. Szymczycha-Madeja, M. Welna, and W. Zyrnicki, "Multi-element analysis, bioavailability and fractionation of herbal tea products," *Journal of the Brazilian Chemical Society*, vol. 24, no. 5, pp. 777–787, 2013, doi: 10.5935/0103-5053.20130102.
- [127] S. Vedak and P. S. V Raut, "Study on Antibacterial Compounds from Methanolic Extract of Bark of *Prosopis juliflora* (*Vilayati babhul*)," *International Journal of Pharmaceutical Sciences and Business Management*, vol. 2, pp. 1–14, 2014.
- [128] M. Shahid *et al.*, "Ethnobotanical studies on *Berberis aristata* DC. root extracts," *African Journal of Biotechnology*, vol. 8, no. 4, pp. 556–563, 2009, doi: 10.5897/AJB2009.000-9093.
- [129] M. I. Kazeem, J. O. Adamson, and I. A. Ogunwande, "Modes of inhibition of α -amylase and α -glucosidase by aqueous extract of morinda lucida benth leaf," *BioMed Research International*, vol. 2013, 2013, doi: 10.1155/2013/527570.
- [130] K. Kevrekidis and B. S. Galil, "Mediterranean Marine Science," vol. 4, pp. 57–66, 2003.
- [131] D. K. Choudhary, N. Chaturvedi, A. Singh, and A. Mishra, "OUP accepted manuscript," *Toxicology Research*, no. December 2019, pp. 1–15, 2020, doi: 10.1093/toxres/tfaa025.
- [132] A. Manuscript, "Docking an," vol. 26, no. 6, pp. 675–686, 2012, doi: 10.1007/s10822-012-9547-0.Docking.
- [133] C. H. Ngan, D. R. Hall, B. Zerbe, L. E. Grove, D. Kozakov, and S. Vajda, "FtSite: High accuracy detection of ligand binding sites on unbound protein structures," *Bioinformatics*, vol. 28, no. 2, pp. 286–287, 2012, doi: 10.1093/bioinformatics/btr651.
- [134] A. Lauria, M. Ippolito, and A. M. Almerico, "Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors.," *Computational biology and chemistry*, vol. 33, no. 5, pp. 386–390, Oct. 2009, doi: 10.1016/j.compbiolchem.2009.07.010.
- [135] P. Geng, F. Qiu, Y. Zhu, and G. Bai, "Four acarviosin-containing oligosaccharides identified from *Streptomyces coelicoflavus* ZG0656 are potent inhibitors of α -amylase," *Carbohydrate Research*, vol. 343, no. 5, pp. 882–892, 2008, doi: 10.1016/j.carres.2008.01.020.

- [136] A. H. Gilani and K. H. Janbaz, "Preventive and curative effects of *Berberis aristata* Fruit extract on paracetamol- and CCl₄-induced hepatotoxicity," *Phytotherapy Research*, vol. 9, no. 7, pp. 489–494, 1995, doi: 10.1002/ptr.2650090705.
- [137] S. M. Kapgate and A. B. Patil, "Integrative Approach in Management of Antitubercular drug Induced hepatotoxicity," no. 1, 2015.
- [138] J. Ahamad, S. R. Mir, and K. J. Naquvi, "Hypoglycemic activity of aqueous extract of *Berberis aristata* stems bark in STZ-induced rats," *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 4, no. 2, pp. 473–474, 2012.
- [139] J. Singh and P. Kakkar, "Antihyperglycemic and antioxidant effect of *Berberis aristata* root extract and its role in regulating carbohydrate metabolism in diabetic rats," *Journal of Ethnopharmacology*, vol. 123, no. 1, pp. 22–26, 2009, doi: <https://doi.org/10.1016/j.jep.2009.02.038>.
- [140] A. Kumar, S. Aswal, R. B. Semwal, A. Chauhan, S. K. Joshi, and D. K. Semwal, "Role of plant-derived alkaloids against diabetes and diabetes-related complications: a mechanism-based approach," *Phytochemistry Reviews*, vol. 18, no. 5, pp. 1277–1298, 2019, doi: 10.1007/s11101-019-09648-6.
- [141] B. John, C. T. Sulaiman, S. George, and V. R. K. Reddy, "Spectrophotometric estimation of total alkaloids in selected justicia species," *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 6, no. 5, pp. 647–648, 2014.
- [142] V. Pulivarthi, P. Josthna, and C. V. Naidu, "in Vitro Antidiabetic Activity By Glucose Uptake of Yeast Cell Assay and Antioxidant Potential of *Annona Reticulata L.* Leaf Extracts," *International Journal of Pharmaceutical Sciences and Drug Research*, vol. 12, no. 3, pp. 208–213, 2020, doi: 10.25004/ijpsdr.2020.120301.
- [143] X. Gao, X. Cai, W. Yang, Y. Chen, X. Han, and L. Ji, "Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations," *Journal of Diabetes Investigation*, vol. 9, no. 2, pp. 321–331, 2018, doi: 10.1111/jdi.12711.
- [144] B. Elya, K. Basah, A. Mun'Im, W. Yulastuti, A. Bangun, and E. K. Septiana, "Screening of α -glucosidase inhibitory activity from some plants of Apocynaceae, Clusiaceae, Euphorbiaceae, and Rubiaceae," *Journal of Biomedicine and Biotechnology*, vol. 2012, 2012, doi: 10.1155/2012/281078.

- [145] S. Kumari, R. Saini, A. Bhatnagar, and A. Mishra, "HR-LCMS and evaluation of anti-diabetic activity of *Hemidesmus indicus* (*anantmool*): Kinetic study, and molecular modelling approach," *Computational Biology and Chemistry*, vol. 105, no. May, p. 107896, 2023, doi: 10.1016/j.compbiolchem.2023.107896.
- [146] S. Forli, R. Huey, M. E. Pique, M. F. Sanner, D. S. Goodsell, and A. J. Olson, "Computational protein–ligand docking and virtual drug screening with the AutoDock suite," *Nature Protocols*, vol. 11, no. 5, pp. 905–919, 2016, doi: 10.1038/nprot.2016.051.
- [147] N. Guex and M. C. Peitsch, "SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.," *Electrophoresis*, vol. 18, no. 15, pp. 2714–2723, Dec. 1997, doi: 10.1002/elps.1150181505.
- [148] A. Bhatnagar, R. Saini, P. Dagar, and A. Mishra, "Molecular modelling and in vitro studies of *Daruharidra* as a potent alpha-amylase inhibitor," *Journal of Biomolecular Structure and Dynamics*, vol. 0, no. 0, pp. 1–12, 2022, doi: 10.1080/07391102.2022.2058093.
- [149] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in *Advanced Drug Delivery Reviews* 23 (1997) 3," *Advanced Drug Delivery Reviews*, vol. 46, no. 1, pp. 3–26, 2001, doi: [https://doi.org/10.1016/S0169-409X\(00\)00129-0](https://doi.org/10.1016/S0169-409X(00)00129-0).
- [150] A. Daina, O. Michielin, and V. Zoete, "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules," *Scientific Reports*, vol. 7, no. 1, p. 42717, 2017, doi: 10.1038/srep42717.
- [151] R. Hardman, "A toxicologic review of quantum dots: Toxicity depends on physicochemical and environmental factors," *Environmental Health Perspectives*, vol. 114, no. 2, pp. 165–172, 2006, doi: 10.1289/ehp.8284.
- [152] M. Athar Abbasi *et al.*, "Synthesis of novel N-(1,3-thiazol-2-yl)benzamide clubbed oxadiazole scaffolds: Urease inhibition, Lipinski rule and molecular docking analyses," *Bioorganic Chemistry*, vol. 83, pp. 63–75, 2019, doi: <https://doi.org/10.1016/j.bioorg.2018.10.018>.

- [153] S. D. Krämer *et al.*, “When barriers ignore the ‘rule-of-five,’” *Advanced Drug Delivery Reviews*, vol. 101, pp. 62–74, 2016, doi: 10.1016/j.addr.2016.02.001.
- [154] A. Rahman and A. A. Ansari, “Alkaloids of *Berberis aristata*: isolation of aromoline and oxyberberine,” *J Chem Soc Pak*, vol. 5, no. 4, p. 283, 1983.
- [155] H. Nuhu and A. Ghani, “Alkaloid content of the leaves of three Nigerian *Datura* species,” *Nigerian Journal of Natural Products and Medicine*, vol. 6, no. 1, pp. 15–18, 2002.
- [156] G. Lalita, Chauhan ; Shalini, “Journal of drug delivery and therapeutics (jddt),” *Journal of Drug Delivery & Therapeutics*, vol. 9, no. 3, pp. 661–668, 2020.
- [157] Priti and S. Rani, “Estimation of Total Alkaloids in Wild and in-Vitro Regenerated *Tinospora Cordifolia*,” *International Journal of Pharmaceutical Sciences and Research*, vol. 10, no. 6, pp. 2777–2784, 2019, doi: 10.13040/IJPSR.0975-8232.10(6).2777-84.
- [158] E. H. Alici and G. Arabaci, “Determination of SOD, POD, PPO and cat enzyme activities in *Rumex obtusifolius L.*,” *Annual Research and Review in Biology*, vol. 11, no. 3, pp. 1–7, 2016, doi: 10.9734/ARRB/2016/29809.
- [159] M. A. Bhutkar, S. D. Bhinge, D. S. Randive, and G. H. Wadkar, “Hypoglycemic effects of *Berberis aristata* and *Tamarindus indica* extracts in vitro,” *Bulletin of Faculty of Pharmacy, Cairo University*, vol. 55, no. 1, pp. 91–94, 2017, doi: 10.1016/j.bfopcu.2016.09.001.
- [160] N. Santhiya, S. Priyanga, S. Hemmalakshmi, and K. Devaki, “Phytochemical analysis, anti-inflammatory activity, in vitro antidiabetic activity and GC-MS profile of *Erythrina variegata L.* bark,” *Journal of Applied Pharmaceutical Science*, vol. 6, no. 7, pp. 147–155, 2016, doi: 10.7324/JAPS.2016.60722.
- [161] P. Suriyamoorthy, H. Subrhamanian, and ..., “Comparative phytochemical investigation of leaf, stem, flower and seed extracts of *Macrotyloma uniflorum L.*,” *Indo Am J Pharm ...*, no. November, 2014.
- [162] T. Dai, J. Chen, D. J. McClements, T. Li, and C. Liu, “Investigation the interaction between procyanidin dimer and α -glucosidase: Spectroscopic analyses and molecular docking simulation,” *International Journal of Biological Macromolecules*, vol. 130, pp. 315–322, 2019, doi: 10.1016/j.ijbiomac.2019.02.105.
- [163] Y. Gong, X. Y. Qin, Y. Y. Zhai, H. Hao, J. Lee, and Y. D. Park, “Inhibitory effect of hesperetin on α -glucosidase: Molecular dynamics simulation integrating inhibition kinetics,”

International Journal of Biological Macromolecules, vol. 101, pp. 32–39, 2017, doi: 10.1016/j.ijbiomac.2017.03.072.

- [164] K. Shivaji *et al.*, “Green-Synthesis-Derived CdS Quantum Dots Using Tea Leaf Extract: Antimicrobial, Bioimaging, and Therapeutic Applications in Lung Cancer Cells,” *ACS Applied Nano Materials*, vol. 1, no. 4, pp. 1683–1693, 2018, doi: 10.1021/acsanm.8b00147.
- [165] P. Deepak, V. Amutha, C. Kamaraj, G. Balasubramani, D. Aiswarya, and P. Perumal, Chemical and green synthesis of nanoparticles and their efficacy on cancer cells. *Elsevier Inc.*, 2019. doi: 10.1016/b978-0-08-102579-6.00016-2.
- [166] F. Radnia, N. Mohajeri, and N. Zarghami, “New insight into the engineering of green carbon dots: Possible applications in emerging cancer theranostics,” *Talanta*, vol. 209, no. November 2019, p. 120547, 2020, doi: 10.1016/j.talanta.2019.120547.
- [167] H. S. Han, S. Y. Koo, and K. Y. Choi, “Emerging nanoformulation strategies for phytochemicals and applications from drug delivery to phototherapy to imaging,” *Bioactive Materials*, vol. 14, no. October 2021, pp. 182–205, 2022, doi: 10.1016/j.bioactmat.2021.11.027.
- [168] A. Valizadeh *et al.*, “Quantum dots: Synthesis, bioapplications, and toxicity,” *Nanoscale Research Letters*, vol. 7, pp. 19–21, 2012, doi: 10.1186/1556-276X-7-480.
- [169] A. V. Kukhta, E. E. Kolesnik, A. I. Lesnikovich, M. N. Nichik, A. N. Kudlash, and S. A. Vorobyova, “Organic-inorganic nanocomposites: Optical and electrophysical properties,” *Synthesis and Reactivity in Inorganic, Metal-Organic and Nano-Metal Chemistry*, vol. 37, no. 5, pp. 333–339, 2007, doi: 10.1080/15533170701392396.
- [170] X. Chen, L. Li, Y. Lai, J. Yan, Y. Tang, and X. Wang, “Microwave-Assisted Synthesis of Glutathione-Capped CdTe/CdSe Near-Infrared Quantum Dots for Cell Imaging,” *International Journal of Molecular Sciences*, vol. 16, no. 5, pp. 11500–11508, 2015, doi: 10.3390/ijms160511500.
- [171] R. J. Tayade, T. S. Natarajan, and H. C. Bajaj, “Photocatalytic Degradation of Methylene Blue Dye Using Ultraviolet Light Emitting Diodes,” *Industrial & Engineering Chemistry Research*, vol. 48, no. 23, pp. 10262–10267, Dec. 2009, doi: 10.1021/ie9012437.

- [172] S. K., T. T., B. P., K. P., S. Santra, and S. M., “Green synthesis of silver nanoparticles using stem extract of *Berberis aristata* and to study characterization and its antimicrobial activity.,” *Journal of Pharmacy Research*, vol. 12, no. March, p. 840, 2018.
- [173] H. Chandra, D. Patel, P. Kumari, J. S. Jangwan, and S. Yadav, “Phyto-mediated synthesis of zinc oxide nanoparticles of *Berberis aristata*: Characterization, antioxidant activity and antibacterial activity with special reference to urinary tract pathogens,” *Materials Science and Engineering C*, vol. 102, no. April, pp. 212–220, 2019, doi: 10.1016/j.msec.2019.04.035.
- [174] A. Kumar, K. R. Singh, M. D. Ghate, H. Lalhlenmawia, D. Kumar, and J. Singh, “Bioinspired quantum dots for cancer therapy: A mini-review,” *Materials Letters*, vol. 313, no. November 2021, p. 131742, 2022, doi: 10.1016/j.matlet.2022.131742.
- [175] S. Yeh, K. Wei, Y. Sun, U. Jeng, and K. S. Liang, “Morphological Transformation of PS-,” pp. 7903–7907, 2003.
- [176] A. Bahuguna, I. Khan, V. K. Bajpai, and S. C. Kang, “MTT assay to evaluate the cytotoxic potential of a drug,” *Bangladesh Journal of Pharmacology*, vol. 12, no. 2, pp. 115–118, 2017, doi: 10.3329/bjp.v12i2.30892.
- [177] D. A. Scudiero *et al.*, “Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.,” *Cancer research*, vol. 48, no. 17, pp. 4827–4833, Sep. 1988.
- [178] Z. Darzynkiewicz, E. Bedner, and P. Smolewski, “Flow cytometry in analysis of cell cycle and apoptosis,” *Seminars in Hematology*, vol. 38, no. 2, pp. 179–193, 2001, doi: 10.1016/S0037-1963(01)90051-4.
- [179] I. Vermes, C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger, “A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.,” *Journal of immunological methods*, vol. 184, no. 1, pp. 39–51, Jul. 1995, doi: 10.1016/0022-1759(95)00072-i.
- [180] M. D. Rao and G. Pennathur, “Green synthesis and characterization of cadmium sulphide nanoparticles from *Chlamydomonas reinhardtii* and their application as photocatalysts,” *Materials Research Bulletin*, vol. 85, pp. 64–73, 2017, doi: 10.1016/j.materresbull.2016.08.049.

- [181] A. Regmi, Y. Basnet, S. Bhattarai, and S. K. Gautam, "Cadmium Sulfide Nanoparticles: Synthesis, Characterization, and Antimicrobial Study," *Journal of Nanomaterials*, vol. 2023, 2023, doi: 10.1155/2023/8187000.
- [182] H. Chandra, D. Patel, P. Kumari, J. S. Jangwan, and S. Yadav, "Phyto-mediated synthesis of zinc oxide nanoparticles of *Berberis aristata*: Characterization, antioxidant activity and antibacterial activity with special reference to urinary tract pathogens," *Materials Science and Engineering C*, vol. 102, no. July 2018, pp. 212–220, 2019, doi: 10.1016/j.msec.2019.04.035.
- [183] B. R. Singh, B. N. Singh, W. Khan, H. B. Singh, and A. H. Naqvi, "ROS-mediated apoptotic cell death in prostate cancer LNCaP cells induced by biosurfactant stabilized CdS quantum dots.," *Biomaterials*, vol. 33, no. 23, pp. 5753–5767, Aug. 2012, doi: 10.1016/j.biomaterials.2012.04.045.
- [184] A. Ghasempour *et al.*, "Cadmium Sulfide Nanoparticles: Preparation, Characterization, and Biomedical Applications.," *Molecules (Basel, Switzerland)*, vol. 28, no. 9, May 2023, doi: 10.3390/molecules28093857.
- [185] I. Ul, H. Bhat, and Y. S. Yi, "Green synthesis and antibacterial activity of cadmium sulfide nanoparticles (CdSNPs) using *Panicum sarmentosum*," *Asian Journal of Green Chemistry*, vol. 3, no. 4, pp. 455–469, 2019, doi: 10.33945/sami/ajgc.2019.4.3.
- [186] I. U. Haq Bhat and Y. S. Yi, "Green synthesis and antibacterial activity of cadmium sulfide nanoparticles (CdSNPs) using *Panicum sarmentosum*," *Asian Journal of Green Chemistry*, vol. 3, no. 4, pp. 455–469, 2019, doi: 10.33945/SAMI/AJGC.2019.4.3.
- [187] Y. Bendale, V. Bendale, and S. Paul, "Evaluation of cytotoxic activity of platinum nanoparticles against normal and cancer cells and its anticancer potential through induction of apoptosis," *Integrative Medicine Research*, vol. 6, no. 2, pp. 141–148, 2017, doi: 10.1016/j.imr.2017.01.006.
- [188] G. Koopman, C. P. Reutelingsperger, G. A. Kuijten, R. M. Keehnen, S. T. Pals, and M. H. van Oers, "Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.," *Blood*, vol. 84, no. 5, pp. 1415–1420, Sep. 1994.
- [189] A. Lezaja and M. Altmeyer, "Inherited DNA lesions determine G1 duration in the next cell cycle," *Cell Cycle*, vol. 17, no. 1, pp. 24–32, 2018, doi: 10.1080/15384101.2017.1383578.

- [190] P. Pozarowski and Z. Darzynkiewicz, "Analysis of cell cycle by flow cytometry.," *Methods in molecular biology (Clifton, N.J.)*, vol. 281, no. April, pp. 301–311, 2004, doi: 10.1385/1-59259-811-0:301.
- [191] A. Siavoshi, M. Taghizadeh, E. Dookhe, and M. Piran, "Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data," *Genomics*, vol. 114, no. 1, pp. 161–170, 2022, doi: 10.1016/j.ygeno.2021.11.031.
- [192] W. Guo *et al.*, "Effect of hyperoside on cervical cancer cells and transcriptome analysis of differentially expressed genes," *Cancer Cell Int*, vol. 19, no. 1, pp. 1–14, 2019, doi: 10.1186/s12935-019-0953-4.
- [193] L. Chen, Y. H. Zhang, G. Lu, T. Huang, and Y. D. Cai, "Analysis of cancer-related lncRNAs using gene ontology and KEGG pathways," *Artif Intell Med*, vol. 76, pp. 27–36, 2017, doi: 10.1016/j.artmed.2017.02.001.
- [194] M. D. Young, M. J. Wakefield, G. K. Smyth, and A. Oshlack, "Gene ontology analysis for RNA-seq: accounting for selection bias," *Genome Biol*, vol. 11, no. 2, 2010, doi: 10.1186/gb-2010-11-2-r14.
- [195] H. Ogata, S. Goto, W. Fujibuchi, and M. Kanehisa, "Computation with the KEGG pathway database," *BioSystems*, vol. 47, no. 1–2, pp. 119–128, 1998, doi: 10.1016/S0303-2647(98)00017-3.
- [196] W. Yasui, N. Oue, R. Ito, K. Kuraoka, and H. Nakayama, "Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications," *Cancer Sci*, vol. 95, no. 5, pp. 385–392, 2004, doi: 10.1111/j.1349-7006.2004.tb03220.x.
- [197] X. Wang, L. Han, L. Zhou, L. Wang, and L. M. Zhang, "Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network," *Oncol Rep*, vol. 40, no. 5, pp. 2659–2673, 2018, doi: 10.3892/or.2018.6707.
- [198] L. Ferrall, K. Y. Lin, R. B. S. Roden, C. F. Hung, and T. C. Wu, "Cervical cancer immunotherapy: Facts and hopes," *Clinical Cancer Research*, vol. 27, no. 18, pp. 4953–4973, 2021, doi: 10.1158/1078-0432.CCR-20-2833.

- [199] Shaokai Zhang, H. Xu, L. Zhang, and Y. Qiao, "Cervical cancer: Epidemiology, risk factors and screening," *Chinese Journal of Cancer Research*, vol. 32, no. 6, pp. 720–728, 2020, doi: 10.21147/j.issn.1000-9604.2020.06.05.
- [200] P. E. Castle, M. H. Einstein, and V. V. Sahasrabudhe, "Cervical cancer prevention and control in women living with human immunodeficiency virus," *CA Cancer J Clin*, vol. 71, no. 6, pp. 505–526, 2021, doi: 10.3322/caac.21696.
- [201] K. Sandra and P. Adum, "Transcriptomic study of the cell death-related pathways of cervical cancer HeLa cells in response to *Clinacanthus nutans* treatment," pp. 1–24, 2022.
- [202] V. Jain, S. Jain, and S. C. Mahajan, "Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment," *Curr Drug Deliv*, vol. 12, no. 2, pp. 177–191, 2015, doi: 10.2174/1567201811666140822112516.
- [203] X. Zhao *et al.*, "Synthesis of dual functional procaine-derived carbon dots for bioimaging and anticancer therapy," *Nanomedicine*, vol. 15, no. 7, pp. 677–689, 2020, doi: 10.2217/nnm-2019-0390.
- [204] K. Shivaji *et al.*, "Utilization of waste tea leaves as bio-surfactant in CdS quantum dots synthesis and their cytotoxicity effect in breast cancer cells," *Appl Surf Sci*, vol. 487, no. May, pp. 159–170, 2019, doi: 10.1016/j.apsusc.2019.05.050.
- [205] M. N. Borovaya, A. P. Naumenko, N. A. Matvieieva, Y. B. Blume, and A. I. Yemets, "Biosynthesis of luminescent CdS quantum dots using plant hairy root culture," *Nanoscale Res Lett*, vol. 9, no. 1, pp. 1–7, 2014, doi: 10.1186/1556-276X-9-686.
- [206] N. Chen *et al.*, "The cytotoxicity of cadmium-based quantum dots," *Biomaterials*, vol. 33, no. 5, pp. 1238–1244, 2012, doi: 10.1016/j.biomaterials.2011.10.070.
- [207] K. Shivaji *et al.*, "Green-Synthesis-Derived CdS Quantum Dots Using Tea Leaf Extract: Antimicrobial, Bioimaging, and Therapeutic Applications in Lung Cancer Cells," *ACS Appl Nano Mater*, vol. 1, no. 4, pp. 1683–1693, Apr. 2018, doi: 10.1021/acsanm.8b00147.
- [208] F. Jahan, S. S. Alvi, and M. H. Islam, "*Berberis aristata* and its secondary metabolites: Insights into nutraceutical and therapeutical applications," *Pharmacological Research - Modern Chinese Medicine*, vol. 5, no. October, p. 100184, 2022, doi: 10.1016/j.prmcm.2022.100184.

- [209] B. Malhotra *et al.*, “Recent advances on *Berberis aristata* emphasizing berberine alkaloid including phytochemistry, pharmacology and drug delivery system,” *J Herb Med*, vol. 27, p. 100433, 2021, doi: <https://doi.org/10.1016/j.hermed.2021.100433>.
- [210] D. Potdar, R. R. Hirwani, and S. Dhulap, “Phyto-chemical and pharmacological applications of *Berberis aristata*,” *Fitoterapia*, vol. 83, no. 5, pp. 817–830, 2012.
- [211] Q. Sheng *et al.*, “Multi-perspective quality control of Illumina RNA sequencing data analysis,” *Brief Funct Genomics*, vol. 16, no. 4, pp. 194–204, 2017.
- [212] M. Puchta, M. Boczkowska, and J. Groszyk, “Low RIN value for RNA-seq library construction from long-term stored seeds: a case study of barley seeds,” *Genes (Basel)*, vol. 11, no. 10, p. 1190, 2020.
- [213] B. K. Padhi, M. Singh, M. Rosales, G. Pelletier, and S. Cakmak, “A PCR-based quantitative assay for the evaluation of mRNA integrity in rat samples,” *Biomol Detect Quantif*, vol. 15, pp. 18–23, May 2018, doi: [10.1016/j.bdq.2018.02.001](https://doi.org/10.1016/j.bdq.2018.02.001).
- [214] A. Siavoshi, M. Taghizadeh, E. Dookhe, and M. Piran, “Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data,” *Genomics*, vol. 114, no. 1, pp. 161–170, 2022.
- [215] D. R. Sojka *et al.*, “Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment,” *Sci Rep*, vol. 9, no. 1, p. 14394, Oct. 2019, doi: [10.1038/s41598-019-50840-7](https://doi.org/10.1038/s41598-019-50840-7).
- [216] Z. Zhou *et al.*, “The acid-sensing ion channel, ASIC2, promotes invasion and metastasis of colorectal cancer under acidosis by activating the calcineurin/NFAT1 axis,” *Journal of Experimental & Clinical Cancer Research*, vol. 36, no. 1, p. 130, Dec. 2017, doi: [10.1186/s13046-017-0599-9](https://doi.org/10.1186/s13046-017-0599-9).
- [217] Z. Meng *et al.*, “HMOX1 upregulation promotes ferroptosis in diabetic atherosclerosis,” *Life Sci*, vol. 284, p. 119935, Nov. 2021, doi: [10.1016/j.lfs.2021.119935](https://doi.org/10.1016/j.lfs.2021.119935).
- [218] M. Cui, Z. Wang, L.-T. Huang, and J.-H. Wang, “Parthenolide leads to proteomic differences in thyroid cancer cells and promotes apoptosis,” *BMC Complement Med Ther*, vol. 22, no. 1, p. 99, Dec. 2022, doi: [10.1186/s12906-022-03579-0](https://doi.org/10.1186/s12906-022-03579-0).

- [219] B. Son *et al.*, “Radiotherapy in combination with hyperthermia suppresses lung cancer progression via increased NR4A3 and KLF11 expression,” *Int J Radiat Biol*, vol. 95, no. 12, pp. 1696–1707, Dec. 2019, doi: 10.1080/09553002.2019.1665213.
- [220] C. Shi, X. Yang, X. Bu, N. Hou, and P. Chen, “Alpha B-crystallin promotes the invasion and metastasis of colorectal cancer via epithelial-mesenchymal transition,” *Biochem Biophys Res Commun*, vol. 489, no. 4, pp. 369–374, Aug. 2017, doi: 10.1016/j.bbrc.2017.05.070.
- [221] A. Klug, “Zinc finger peptides for the regulation of gene expression,” *J Mol Biol*, vol. 293, no. 2, pp. 215–218, Oct. 1999, doi: 10.1006/jmbi.1999.3007.
- [222] K. L. Lorick, J. P. Jensen, S. Fang, A. M. Ong, S. Hatakeyama, and A. M. Weissman, “RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination,” *Proceedings of the National Academy of Sciences*, vol. 96, no. 20, pp. 11364–11369, Sep. 1999, doi: 10.1073/pnas.96.20.11364.
- [223] J. H. Laity, B. M. Lee, and P. E. Wright, “Zinc finger proteins: new insights into structural and functional diversity,” *Curr Opin Struct Biol*, vol. 11, no. 1, pp. 39–46, Feb. 2001, doi: 10.1016/S0959-440X(00)00167-6.
- [224] A. Becchetti, “Ion channels and transporters in cancer. 1. Ion channels and cell proliferation in cancer,” *American Journal of Physiology-Cell Physiology*, vol. 301, no. 2, pp. C255–C265, Aug. 2011, doi: 10.1152/ajpcell.00047.2011.
- [225] E. Boedtkjer, “Ion Channels, Transporters, and Sensors Interact with the Acidic Tumor Microenvironment to Modify Cancer Progression,” in *From Malignant Transformation to Metastasis: Ion Transport in Tumor Biology*, C. Stock and L. A. Pardo, Eds., Cham: Springer International Publishing, 2022, pp. 39–84. doi: 10.1007/112_2021_63.
- [226] C. Zhu, Y. Wei, and X. Wei, “AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications,” *Mol Cancer*, vol. 18, pp. 1–22, 2019.
- [227] G. R. Monteith, N. Prevarskaya, and S. J. Roberts-Thomson, “The calcium–cancer signalling nexus,” *Nat Rev Cancer*, vol. 17, no. 6, pp. 373–380, 2017.
- [228] N. Prevarskaya, H. Ouadid-Ahidouch, R. Skryma, and Y. Shuba, “Remodelling of Ca²⁺ transport in cancer: how it contributes to cancer hallmarks?,” *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 369, no. 1638, p. 20130097, 2014.

- [229] S. Kuchay *et al.*, “PTEN counteracts FBXL2 to promote IP3R3-and Ca²⁺-mediated apoptosis limiting tumour growth,” *Nature*, vol. 546, no. 7659, pp. 554–558, 2017.
- [230] A. D. Tripathi, S. Katiyar, and A. Mishra, “Glypican1: a potential cancer biomarker for nanotargeted therapy,” *Drug Discov Today*, p. 103660, 2023.
- [231] T.-H. Li *et al.*, “IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/ β -catenin signaling,” *Cellular Oncology*, vol. 44, no. 6, pp. 1425–1437, 2021.
- [232] Z. Yang *et al.*, “A pilot study on polycystic ovarian syndrome caused by neonatal exposure to tributyltin and bisphenol A in rats,” *Chemosphere*, vol. 231, pp. 151–160, Sep. 2019, doi: 10.1016/j.chemosphere.2019.05.129.
- [233] Y. Gao *et al.*, “miR-335-5p suppresses gastric cancer progression by targeting MAPK10,” *Cancer Cell Int*, vol. 21, no. 1, pp. 1–12, 2021.
- [234] R. Sun *et al.*, “19q13 KRAB zinc-finger protein ZNF471 activates MAPK10/JNK3 signaling but is frequently silenced by promoter CpG methylation in esophageal cancer,” *Theranostics*, vol. 10, no. 5, p. 2243, 2020.
- [235] B. Qiao, Q. Wang, Y. Zhao, and J. Wu, “miR-205-3p functions as a tumor suppressor in ovarian carcinoma,” *Reproductive Sciences*, vol. 27, pp. 380–388, 2020.
- [236] L. Qi and Y. Ding, “Potential antitumor mechanisms of phenothiazine drugs,” *Sci China Life Sci*, vol. 56, pp. 1020–1027, 2013.
- [237] C. A. Calderón-Ospina and M. O. Nava-Mesa, “B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin,” *CNS Neurosci Ther*, vol. 26, no. 1, pp. 5–13, 2020.
- [238] D. Lonsdale, “A review of the biochemistry, metabolism and clinical benefits of thiamin (e) and its derivatives,” *Evidence-Based Complementary and Alternative Medicine*, vol. 3, pp. 49–59, 2006.
- [239] A. U. Ahmed, “An overview of inflammation: mechanism and consequences,” *Frontiers in Biology*, vol. 6, no. 4, pp. 274–281, 2011, doi: 10.1007/s11515-011-1123-9.

- [240] S. Anees Ali Jafri *et al.*, “Evaluation of some essential traditional medicinal plants for their potential free scavenging and antioxidant properties,” *Journal of King Saud University - Science*, vol. 35, no. 3, p. 102562, 2023, doi: 10.1016/j.jksus.2023.102562.
- [241] A. Phogat, J. Singh, V. Kumar, and V. Malik, “Berberine mitigates acetamiprid-induced hepatotoxicity and inflammation via regulating endogenous antioxidants and NF- κ B/TNF- α signaling in rats,” *Environmental Science and Pollution Research*, vol. 30, no. 37, pp. 87412–87423, 2023, doi: 10.1007/s11356-023-28279-1.
- [242] V. Dubey, J. Kansagra, V. Sureja, and D. Kheni, “Efficacy evaluation of *Berberis aristata* and *Silybum marianum* fixed dose combination on glycaemic and insulin resistance parameters in adult population: a systematic review and meta-analysis of randomized controlled trials,” *Future Journal of Pharmaceutical Sciences*, vol. 10, no. 1, p. 28, 2024, doi: 10.1186/s43094-024-00603-7.
- [243] P. Tamane, K. Mahadik, and V. Pokharkar, “Buccal spray of standardized *Berberis aristata* extract causes tumour regression, chemoprotection and downregulation of inflammatory mediators in oral cancer hamster model,” *Journal of Ethnopharmacology*, vol. 317, p. 116732, 2023, doi: <https://doi.org/10.1016/j.jep.2023.116732>.
- [244] “NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.,” *Lancet (London, England)*, vol. 396, no. 10255, pp. 918–934, Sep. 2020, doi: 10.1016/S0140-6736(20)31761-X.
- [245] H. Yu, L. Lin, Z. Zhang, H. Zhang, and H. Hu, “Targeting NF- κ B pathway for the therapy of diseases: mechanism and clinical study,” *Signal Transduction and Targeted Therapy*, vol. 5, no. 1, p. 209, 2020, doi: 10.1038/s41392-020-00312-6.
- [246] C. W. Wong, W. K. Seow, J. W. O’Callaghan, and Y. H. Thong, “Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor.,” *Agents and actions*, vol. 36, no. 1–2, pp. 112–118, May 1992, doi: 10.1007/BF01991238.
- [247] C. W. Wong, Y. H. Thong, and W. K. Seow, “Comparative effects of tetrandrine and berbamine on guineapig airway microvascular leakage induced by platelet-activating factor and other allergic mediators,” *International Journal of Immunopharmacology*, vol. 15, no. 2, pp. 185–193, 1993, doi: [https://doi.org/10.1016/0192-0561\(93\)90094-F](https://doi.org/10.1016/0192-0561(93)90094-F).

- [248] Y. Liang, R.-Z. Xu, L. Zhang, and X.-Y. Zhao, "Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.," *Acta pharmacologica Sinica*, vol. 30, no. 12, pp. 1659–1665, Dec. 2009, doi: 10.1038/aps.2009.167.
- [249] Y.-L. Wei, Y. Liang, L. Xu, and X.-Y. Zhao, "The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.," *Anatomical record (Hoboken, N.J. : 2007)*, vol. 292, no. 7, pp. 945–950, Jul. 2009, doi: 10.1002/ar.20924.
- [250] L. Liu, Z. Xu, B. Yu, L. Tao, and Y. Cao, "Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways.," *Evidence-based complementary and alternative medicine : eCAM*, vol. 2021, p. 5517143, 2021, doi: 10.1155/2021/5517143.
- [251] X. J. Jia, X. Li, F. Wang, H. Q. Liu, D. J. Zhang, and Y. Chen, "Berbamine exerts anti-inflammatory effects via inhibition of NF-κB and MAPK signaling pathways," *Cellular Physiology and Biochemistry*, vol. 41, no. 6, pp. 2307–2318, 2017, doi: 10.1159/000475650.
- [252] F. Hajiaghaalipour, M. S. Kanthimathi, M. A. Abdulla, and J. Sanusi, "The Effect of *Camellia sinensis* on Wound Healing Potential in an Animal Model.," *Evidence-based complementary and alternative medicine : eCAM*, vol. 2013, p. 386734, 2013, doi: 10.1155/2013/386734.
- [253] K. Ofori-Kwakye, A. A. Kwapong, and M. T. Bayor, "Wound healing potential of methanol extract of *Spathodea campanulata* stem bark formulated into a topical preparation.," *African journal of traditional, complementary, and alternative medicines : AJTCAM*, vol. 8, no. 3, pp. 218–223, 2011, doi: 10.4314/ajtcam.v8i3.65280.
- [254] P. Bremner *et al.*, "Assessing medicinal plants from South-Eastern Spain for potential anti-inflammatory effects targeting nuclear factor-Kappa B and other pro-inflammatory mediators," *Journal of Ethnopharmacology*, vol. 124, no. 2, pp. 295–305, 2009, doi: 10.1016/j.jep.2009.04.035.
- [255] T. Mechanism, A. Acid, R. Inflammatory, and T. Cox-, *Hironari Akasaka*.
- [256] W. A. van der Donk, A.-L. Tsai, and R. J. Kulmacz, "The Cyclooxygenase Reaction Mechanism," *Biochemistry*, vol. 41, no. 52, pp. 15451–15458, Dec. 2002, doi: 10.1021/bi026938h.

- [257] J. J. Ruitenber and C. A. Waters, "A rapid flow cytometric method for the detection of intracellular cyclooxygenases in human whole blood monocytes and a COX-2 inducible human cell line," *Journal of Immunological Methods*, vol. 274, no. 1, pp. 93–104, 2003, doi: [https://doi.org/10.1016/S0022-1759\(02\)00507-0](https://doi.org/10.1016/S0022-1759(02)00507-0).
- [258] N. Parameswaran and S. Patial, "Tumor necrosis factor- α signaling in macrophages.," *Critical reviews in eukaryotic gene expression*, vol. 20, no. 2, pp. 87–103, 2010, doi: [10.1615/critreveukargeneexpr.v20.i2.10](https://doi.org/10.1615/critreveukargeneexpr.v20.i2.10).
- [259] D.-I. Jang *et al.*, "The Role of Tumor Necrosis Factor Alpha (TNF- α) in Autoimmune Disease and Current TNF- α Inhibitors in Therapeutics.," *International journal of molecular sciences*, vol. 22, no. 5, Mar. 2021, doi: [10.3390/ijms22052719](https://doi.org/10.3390/ijms22052719).
- [260] C. L. Pierri *et al.*, "Molecular modeling of antibodies for the treatment of TNF α -related immunological diseases.," *Pharmacology research & perspectives*, vol. 4, no. 1, p. e00197, Feb. 2016, doi: [10.1002/prp2.197](https://doi.org/10.1002/prp2.197).
- [261] A. Zarghi and S. Arfaei, "Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships.," *Iranian journal of pharmaceutical research : IJPR*, vol. 10, no. 4, pp. 655–683, 2011.
- [262] C. Rawat, S. Kukal, U. R. Dahiya, and R. Kukreti, "Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.," *Journal of neuroinflammation*, vol. 16, no. 1, p. 197, Oct. 2019, doi: [10.1186/s12974-019-1592-3](https://doi.org/10.1186/s12974-019-1592-3).
- [263] D. A. Dixon, C. D. Kaplan, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott, "Post-transcriptional Control of Cyclooxygenase-2 Gene Expression: THE ROLE OF THE 3'-UNTRANSLATED REGION*," *Journal of Biological Chemistry*, vol. 275, no. 16, pp. 11750–11757, 2000, doi: <https://doi.org/10.1074/jbc.275.16.11750>.
- [264] A. Alexanian and A. Sorokin, "Cyclooxygenase 2: protein-protein interactions and posttranslational modifications.," *Physiological genomics*, vol. 49, no. 11, pp. 667–681, Nov. 2017, doi: [10.1152/physiolgenomics.00086.2017](https://doi.org/10.1152/physiolgenomics.00086.2017).

List of publications

Research publication-

- **Aditi Bhatnagar**, Ravi Saini, Priya Dagar and Abha Mishra (2023) ‘Molecular modelling and in vitro studies of *Daruharidra* as a potent alpha-amylase inhibitor’, Journal of Biomolecular Structure and Dynamics. Taylor & Francis, 41(9), pp. 3872–3883. doi:10.1080/07391102.2022.2058093.
- **Aditi Bhatnagar**, Sonali Kumari, Ravi Saini and Abha Mishra (2024) ‘HRLCMS based metabolite profiling of antioxidant and hypoglycaemic properties of *Daruharidra* (*Berberis aristata*): an in vitro and molecular modelling approach’, New Journal of Chemistry. The Royal Society of Chemistry, 48(2), pp. 578–590. doi: 10.1039/D3NJ03494A.
- **Aditi Bhatnagar** and Abha Mishra (2024) ‘Development of *Daruharidra* (*Berberis aristata*) Based Biogenic Cadmium Sulfide Nanoparticles: Their Implementation as Antibacterial and Novel Therapeutic Agents against Human Breast and Ovarian Cancer’, Current Pharmaceutical Biotechnology, pp. 1–12.
doi: <http://dx.doi.org/10.2174/0113892010244977231108043554>.
- Sonali Kumari, **Aditi Bhatnagar**, Ravi Saini and Abha Mishra (2023) ‘HR-LCMS and evaluation of anti-diabetic activity of *Hemidesmus indicus* (*anantmool*): Kinetic study, and molecular modelling approach’, Computational Biology and Chemistry, 105, p. 107896. doi: <https://doi.org/10.1016/j.compbiolchem.2023.107896>.
- Ravi Saini, Sonali Kumari, **Aditi Bhatnagar** and Abha Mishra (2023) ‘Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR CSTMLR mutant protein: molecular modeling and free energy approach’, Scientific Reports, 13(1), p. 8885. doi: 10.1038/s41598-023-33065-7.

Review Publications-

- Sonali Kumari Ravi Saini, **Aditi Bhatnagar** and Abha Mishra, (2023) ‘A comprehensive review on ayurvedic herb *Leptadenia reticulata* (Jeevanti): a phytochemistry and pharmacological perspective’, Natural Product Research. Taylor & Francis, 0(0), pp. 1–27. doi: 10.1080/14786419.2023.2282119.
- Sonali Kumari Ravi Saini, **Aditi Bhatnagar** and Abha Mishra, (2023) ‘Exploring plant-based alpha-glucosidase inhibitors: promising contenders for combatting type-2 diabetes’, Archives of Physiology and Biochemistry. Taylor & Francis, 0(0), pp. 1–16. doi: 10.1080/13813455.2023.2262167.

Book chapters

- **Bhatnagar, A.** and Mishra, A. (2022) ‘ α -Glucosidase Inhibitors for Diabetes/Blood Sugar Regulation’, in Maheshwari, V. L. and Patil, R. H. (eds) Natural Products as Enzyme Inhibitors: An Industrial Perspective. Singapore: Springer Nature Singapore, pp. 269–283. doi: 10.1007/978-981-19-0932-0_12.
- Mishra, A. and **Bhatnagar, A.** (2023) ‘23 - Green synthesis of nanoparticles by endophytes’, in Shah, M. and Deka Why and How, D. B. T.-E. A. W. (eds) Developments in Applied Microbiology and Biotechnology. Academic Press, pp. 487–502. doi: <https://doi.org/10.1016/B978-0-323-91245-7.00013-4>.
- Mishra, A., Kumar, S. and **Bhatnagar, A.** (2019) ‘Chapter 7 - Potential of Fungal Laccase in Decolorization of Synthetic Dyes’, in Shah, M. P. and Rodriguez-Couto, S. (eds) Microbial Wastewater Treatment. Elsevier, pp. 127–151. doi: <https://doi.org/10.1016/B978-0-12-816809-7.00007-5>.
- Abhay Dev Tripathi, **Aditi Bhatnagar**, Soumya Katiyar, Abha Mishra, (2023), Mesoporous Silica Nanoparticles for Drug Delivery in Brain Disorders, Nanoarchitectonics for Brain Drug Delivery, Taylor and Francis. <http://dx.doi.org/10.1201/9781032661964-5>.
- Sonali Kumari, Ravi Saini, **Aditi Bhatnagar** and Abha Mishra, *Ichnocarpus frutescens* and Its Role in Alpha-Glucosidase Inhibition, Advances in Health and Disease. Volume 66, Nova.

Conferences and workshops

- International Virtual Workshop ‘Bioelectronic Medicine’2022, jointly organized by IIT (BHU) Varanasi and IISc Bangalore and co-hosted by the Henry Royce Institute, The University of Manchester.
- Winter School on Advanced application of nanotechnology in Food and Environment, 2022, organized by DBT-TDNBC-DEAKIN, Research network across continents for learning and innovation, (DTD-RNA), TERI.
- International workshop on Recent Advances in Interdisciplinary Chemical Sciences (RAICS), 2022, Chemistry (BHU).
- International Conference on Drug Discovery 2022 (ICDD- 2022), hosted by Schrödinger Inc, USA in collaboration with BITS - Pilani Goa Campus.
- Global Sustainability Conference, (GSC-2021), organised by Advanced computing research society.
- Indo-US Conference on Bioengineering and Regenerative Medicine (ICBR-2020), organized by School of biochemical engineering and FIU.